Novartis faced downward pressure on its U.S. shares following the release of late-stage study results for its multiple sclerosis medication. The data indicated that the drug’s ability to reduce flare-ups fell short of the benchmarks established by a competing product from Roche Holding. Meanwhile, UnitedHealth Group saw its share price slip during the session, though the insurer successfully capped off the week with a cumulative gain exceeding 4%.
Health Care Stocks Dip as Investor Rotation Stalls
The health care sector retreated on Friday as the recent market shift toward defensive insurance stocks lost its momentum. Investors paused their rotation out of artificial intelligence holdings, leaving broader health care indices struggling to maintain their footing amid disappointing clinical trial data and uneven performance among industry heavyweights.
Comments (0)
No comments yet. Be the first!